Corrigendum: Familial hypercholesterolemia in the danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication (Journal of Clinical Endocrinology and Metabolism (2012) 97, (3956-3964) DOI: 10.1210/jc.2012-1563);Familial hypercholesterolemia in the Danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 11, 2012, Pages 3956-3964

  Benn, Marianne ^a,d   Watts, Gerald F ^b   Tybjaerg Hansen, Anne ^a,c,d   Nordestgaard, Børge G ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN;

ADULT; AGED; ANGINA PECTORIS; APOB GENE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DANISH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ETHNIC GROUP; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE; GENE MUTATION; HEART INFARCTION; HUMAN; HYPERTENSION; LDLR GENE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SMOKING;

EID: 84868628467     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3926     Document Type: Erratum

References (37)

1. Watts GF, Lewis B, Sullivan DR 2007 Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nat Clin Pract Cardiovasc Med 4:404-405 (Pubitemid 47180321)
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE 2004 Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160:421-429 (Pubitemid 39166974)
3. Austin MA, Hutter CM, Zimmern RL, Humphries SE 2004 Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 160:407-420 (Pubitemid 39166973)
4. Soutar AK, Naoumova RP 2007 Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 4:214-225 (Pubitemid 46502094)
5. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN 1993 Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 72:171-176 (Pubitemid 23205873)
6. National Collaborating Centre for Primary Care 2008 Identification and management of familial hypercholesterolaemia. NICE clinical guideline 71. London: National Institute for Health and Clinical Excellence
7. World Health Organization 1999 Familial hypercholesterolaemia (FH). Report of a second WHO consultation. Geneva: World Health Organization
8. Hadfield SG, Humphries SE 2005 Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol 16:428-433 (Pubitemid 41017627)
9. Catapano AL, Reiner Z, De BG, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone FP, Riccardi G, Storey RF, Wood D 2011 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atheroscler 217(Suppl 1):S1-S44
10. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, O'Brien R, Bishop W, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, et al. 2011 Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 12:221-263
11. Walma EP, Visseren FL, Jukema JW, Kastelein JJ, Hoes AW, Stalenhoef AF 2006 [The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board]. Ned Tijdschr Geneeskd 150:18-23 (Dutch)
12. Jensen HK, Jensen LG, Meinertz H, Hansen PS, Gregersen N, Faergeman O 1999 Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. Atherosclerosis 146:337-344 (Pubitemid 29418065)
13. Damgaard D, Larsen ML, Nissen PH, Jensen JM, Jensen HK, Soerensen VR, Jensen LG, Faergeman O 2005 The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180:155-160
14. Marks D, Thorogood M, Neil HA, Humphries SE 2003 A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168:1-14 (Pubitemid 36559596)
15. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ 2011 Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:S9-S17
16. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE 2000 Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 321:148 (Pubitemid 30447007)
17. Scientific Steering Committee SBRG 1991 Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303:893-896
18. Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ 2001 Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 322:1019-1023
19. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308 (Pubitemid 47080484)
20. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG 2008 Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359:1897-1908
21. Aarden E, Van Hoyweghen I, Horstman K 2011 The paradox of public health genomics: definition and diagnosis of familial hypercholesterolaemia in three European countries. Scand J Public Health 39:634-639
22. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, et al. 2011 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32:1769-1818
23. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW 2003 Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Am J Cardiol 92:152-160 (Pubitemid 36835963)
24. Whitworth JA; World Health Organization; International Society of Hypertension Writing Group 2003 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-1992
25. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith Jr SC; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity 2009 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645
26. Tybjaerg-Hansen A, Jensen HK, Benn M, Steffensen R, Jensen G, Nordestgaard BG 2005 Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations. Arterioscler Thromb Vasc Biol 25:211-215 (Pubitemid 40054278)
27. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D 2008 What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 19:362-368
28. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ 2008 Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337:a2423
29. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE 2008 Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 29:2625-2633
30. Langsted A, Freiberg JJ, Nordestgaard BG 2008 Fasting and non-fasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118:2047-2056
31. Watts GF, Cohn JS 2011 Whither the lipid profile: feast, famine, or no free lunch? Clin Chem 57:363-365
32. Descamps OS, de Meester A, Cheron P, Kastelein JJ, Heller FR 2003 Silent ischaemia in familial hypercholesterolemia. Atheroscler Suppl 4:7-8 (Pubitemid 38234499)
33. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL 2010 Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209:189-194
34. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Reiner Z, Keil U 2010 EUROASPIRE III Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 17:530-540
35. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U 2009 EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16:121-137
36. Siggaard-Andersen N, Freiberg JJ, Nordestgaard BG 2012 Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids. Dan Med J 59:A4470
37. Daniels SR, Gidding SS, de Ferranti SD 2011 Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:S30-S37